Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -16245.70% is 19% above its 3-year average of -20101.77%, near the high end of its 3-year range (-85961.55%–-5883.67%).
20.64% above its 12-month average of -20470.07%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2010 (2010-12-31): -12719.26%.
EBITDA MARGIN
-16245.70%
EBITDA MARGIN AVG TTM
-20470.07%
EBITDA MARGIN AVG 3Y
-20101.77%
EBITDA MARGIN AVG 5Y
-20101.77%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+20.64%
CURRENT VS 3Y AVG
+19.18%
CURRENT VS 5Y AVG
+19.18%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cellectar Biosciences, Inc.
Market Cap
$13.34M
EBITDA Margin
-16245.70%
TTM Avg
-20470.07%
3Y Avg
-20101.77%
5Y Avg
-20101.77%
Market Cap
$12.63M
EBITDA Margin
-1106.68%
TTM Avg
-120183.14%
3Y Avg
-60445.11%
5Y Avg
-60445.11%
Market Cap
$12.46M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
Market Cap
$14.28M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.95M
EBITDA Margin
-1346.05%
TTM Avg
-2835.20%
3Y Avg
-1619.25%
5Y Avg
-1619.25%
Market Cap
$11.41M
EBITDA Margin
-19.85%
TTM Avg
-31.46%
3Y Avg
-46.77%
5Y Avg
-56.23%
Market Cap
$15.30M
EBITDA Margin
-468.17%
TTM Avg
-602.06%
3Y Avg
-602.06%
5Y Avg
-23374.02%
Market Cap
$11.01M
EBITDA Margin
-5650.91%
TTM Avg
-5650.91%
3Y Avg
-12817.85%
5Y Avg
-12817.85%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $13.34M | -16245.70% | -20470.07% | -20101.77% | -20101.77% |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | -1106.68% | -120183.14% | -60445.11% | -60445.11% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | -34.02% | -37.67% | -64.98% | -56.41% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | -1346.05% | -2835.20% | -1619.25% | -1619.25% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.42M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.41M | -19.85% | -31.46% | -46.77% | -56.23% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -468.17% | -602.06% | -602.06% | -23374.02% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | -5650.91% | -5650.91% | -12817.85% | -12817.85% |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-16245.7%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2010-12-31 | -12719.26% |
| 2010-03-31 | -30241.56% |
| 2009-12-31 | -18449.39% |
| 2009-09-30 | -16719.73% |
| 2009-06-30 | -6355.36% |
| 2009-03-31 | -7177.83% |
| 2008-12-31 | -5883.67% |
| 2008-09-30 | -7192.09% |
| 2008-06-30 | -10317.28% |
| 2008-03-31 | -85961.55% |
| 2005-09-30 | -7626.51% |
